429.93
1.69%
+7.15
시간 외 거래:
429.93
Vertex Pharmaceuticals, Inc. 주식(VRTX)의 최신 뉴스
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
The Motley Fool
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
The Motley Fool
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Zacks Investment Research
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks Investment Research
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
Zacks Investment Research
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
The Motley Fool
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
3 No-Brainer Stocks to Buy in May
The Motley Fool
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks Investment Research
Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know
Zacks Investment Research
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
Zacks Investment Research
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
2 Top Growth Stocks to Buy Right Now and Hold Forever
The Motley Fool
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.
The Motley Fool
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks Investment Research
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Zacks Investment Research
2 Fantastic Growth Stocks to Buy Right Now
The Motley Fool
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
The Motley Fool
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Zacks Investment Research
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
The Motley Fool
Making Sense of Amazon CEO Andy Jassy's Latest Letter
The Motley Fool
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
The Motley Fool
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
The Motley Fool
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Zacks Investment Research
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Zacks Investment Research
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
The Motley Fool
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
The Motley Fool
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks Investment Research
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
Zacks Investment Research
Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?
Zacks Investment Research
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
The Motley Fool
Should You Invest in the VanEck Biotech ETF (BBH)?
Zacks Investment Research
Could This Stock Be the Next Biotech Buyout?
The Motley Fool
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
Benzinga
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Zacks Investment Research
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
Benzinga
Vertex Pharmaceuticals: Buy, Sell, or Hold?
The Motley Fool
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks Investment Research
자본화:
|
볼륨(24시간):